Economics of Rotavirus Gastroenteritis and Vaccination in Europe: What Makes Sense?

  title={Economics of Rotavirus Gastroenteritis and Vaccination in Europe: What Makes Sense?},
  author={Richard D. Rheingans and Johan Heylen and Carlo Giaquinto},
  journal={The Pediatric Infectious Disease Journal},
Rotavirus is a major cause of gastroenteritis in children throughout Europe and the world. In addition to causing morbidity and mortality in children, rotavirus gastroenteritis (RVGE) creates a major economic burden on health care systems and families in Europe. The costs of hospital admissions for RVGE and nosocomial infections generate significant medical treatment costs throughout the region. Less information is available on the costs associated with less severe episodes and the costs borne… 

Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom

The results suggest that some of the health sector costs, and all of the societal costs, of rotavirus gastroenteritis in children can be avoided by an immunization programme.

Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.

Rotavirus vaccination can be considered a cost-effective intervention in Israel, depending on the precise vaccine price.

Rotavirus vaccination in Europe: drivers and barriers.

[Economic evaluation of acute paediatric rotavirus gastroenteritis in France].

Rotavirus: Evidence for Vaccination

2 new live orally administered vaccines - Rotarix and RotaTeq - that provide wide protection against RV infections have been developed and demonstrated their excellent efficacy and safety including absence of vaccine-associated intussusception in young infants.

Hospitalizations due to rotavirus gastroenteritis in Catalonia, Spain, 2003-2008

The relatively low incidence of hospitalization due to rotavirus makes rotvirus vaccination less cost-effective in Catalonia than in other areas with higher rotav virus disease burden.

Prevention of childhood rotavirus disease through the use of Rotarix™ and RotaTeq™ vaccines

More data on the efficacy of these two new vaccines in low-income nations are needed, particularly in Asia and Africa, before global inclusion of rotavirus vaccines into national immunisation programmes can be recommended.



Cost-effectiveness analysis of a rotavirus immunization program for the United States.

A US rotavirus immunization program would be cost-effective from the perspectives of society and the health care system, although the cost of the immunizationprogram would not be fully offset by the reduction in health care cost of rotav virus diarrhea unless the price fell to $9 per dose.

Economic impact of community- and nosocomially acquired rotavirus gastroenteritis in Austria

This cost-of-illness study clearly demonstrates the great impact of RV acute gastroenteritis, mainly of nosocomially acquired infection, on medical health care costs in Austria.

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

  • F. AsensiM. de José M. Vento
  • Medicine
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2004
Implementing a universal PCV-7 vaccination program in Spain will significantly decrease the mortality and morbidity associated with pneumococcal infections in young children, comparing favorably with other preventive programs in Spain.

Impact of rotavirus infection on a paediatric hospital in the east end of London.

Rotavirus infections accounted for a significant number of patients treated in casualty, admissions to hospital, and bed occupancy in a paediatric hospital and the estimated cost of treating reported cases of rotavirus in England and Wales is in excess of 6.3 pounds million a year.